Melane Sampson, Author at BioTuesdays

Executive Moves

James Rawls, PharmD, joins LB as SVP of regulatory affairs

LB Pharmaceuticals (NASDAQ: LBRX) has announced the appointment of James Rawls, PharmD, as senior vice president (SVP) of regulatory affairs. With more than 25 years of regulatory leadership experience across global...

October 14, 2025

Developments

CervoMed reports new data from trial showing potential of neflamapimod for DLB

CervoMed (NASDAQ: CRVO) has announced additional data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod’s potential as a treatment for dementia with Lewy bodies (DLB). According to CervoMed, FDA feedback on...

October 8, 2025

Developments

USPTO grants Aquestive two patents for Anaphylm

Aquestive Therapeutics (NASDAQ: AQST) has announced that the USPTO has issued two additional patents extending protection into 2037 for Anaphylm, a novel epinephrine prodrug sublingual film. According to Aquestive, if...

October 8, 2025

Developments

PharmaJet initiates development of needle-free injection pens for home use

Closely held PharmaJet has announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. The single-use and reusable needle-free...

October 7, 2025

Feature

Perimeter mitigating re-excisions with next-gen, AI-powered imaging breakthrough; potential FDA approval on the horizon

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) is an early stage commercial growth company that is pioneering a breakthrough, ultra-high-res, AI-driven intraoperative margin visualization technology called B...

October 7, 2025

Developments

FDA grants ALTO fast track designation for treatment of CIAS

Alto Neuroscience (NYSE: ANRO) announced that the FDA has granted its novel small molecule PDE4 inhibitor, ALTO-101, fast track designation for the treatment of cognitive impairment associated with schizophrenia (CIAS)...

October 6, 2025

Developments

Aspire files omnibus patent application with USPTO for drug delivery platform

Aspire Biopharma Holdings (NASDAQ: ASBP) has announced the filing of an omnibus patent application with the USPTO for its sublingual drug delivery technology. According to Aspire, the technology is designed to enhance...

October 6, 2025

Developments

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of...

October 2, 2025

Executive Moves

Cantargia appoints Dr. Wolfram Dempke as CMO

Cantargia (Nasdaq Stockholm: CANTA) has announced the appointment of Wolfram Dempke, MD, PhD, MBA as chief medical officer (CMO), effective immediately. Dr. Morten Lind Jensen, who has served as CMO since March 2025...

October 2, 2025

Executive Moves

Dr. Tiffany Inglis joins Sera as CMO

Sera Prognostics (NASDAQ: SERA) has announced the appointment of Tiffany Inglis, MD, FACOG, as chief medical officer (CMO). Dr. Inglis brings extensive clinical leadership expertise to Sera. As CMO, she will lead...

October 1, 2025

Author - Melane Sampson

James Rawls, PharmD, joins LB as SVP of regulatory affairs

CervoMed reports new data from trial showing potential of neflamapimod for DLB

USPTO grants Aquestive two patents for Anaphylm

PharmaJet initiates development of needle-free injection pens for home use

Perimeter mitigating re-excisions with next-gen, AI-powered imaging breakthrough; potential FDA approval on the horizon

FDA grants ALTO fast track designation for treatment of CIAS

Aspire files omnibus patent application with USPTO for drug delivery platform

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Cantargia appoints Dr. Wolfram Dempke as CMO

Dr. Tiffany Inglis joins Sera as CMO

Subscribe